Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$0.64
+0.0%		$0.70
$0.55
▼
$1.70
$8.06M1.5247,453 shs14,619 shs
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$1.31
+2.3%		$1.20
$0.62
▼
$6.25
$8.64M1.9520.17 million shs544,953 shs
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
$1.19
$0.37
▼
$14.09
$2.15M2.04220,545 shsN/A
Exicure, Inc. stock logo
XCUR
Exicure
$1.15
-11.5%		$1.81
$1.05
▼
$9.48
$7.53M3.6545,534 shs151,636 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
0.00%-5.82%+1.47%-32.60%-59.22%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
0.00%+7.38%+61.63%-45.19%-57.05%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%0.00%0.00%0.00%-93.29%
Exicure, Inc. stock logo
XCUR
Exicure
0.00%-8.00%-32.75%-59.07%-81.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$0.64
+0.0%		$0.70
$0.55
▼
$1.70
$8.06M1.5247,453 shs14,619 shs
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$1.31
+2.3%		$1.20
$0.62
▼
$6.25
$8.64M1.9520.17 million shs544,953 shs
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
$1.19
$0.37
▼
$14.09
$2.15M2.04220,545 shsN/A
Exicure, Inc. stock logo
XCUR
Exicure
$1.15
-11.5%		$1.81
$1.05
▼
$9.48
$7.53M3.6545,534 shs151,636 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
0.00%-5.82%+1.47%-32.60%-59.22%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
0.00%+7.38%+61.63%-45.19%-57.05%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%0.00%0.00%0.00%-93.29%
Exicure, Inc. stock logo
XCUR
Exicure
0.00%-8.00%-32.75%-59.07%-81.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2.40
Hold$3.07378.94% Upside
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
2.00
HoldN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
1.50
ReduceN/AN/A
Exicure, Inc. stock logo
XCUR
Exicure
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest CLSD, APRE, CELZ, and XCUR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/13/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/13/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$3.00
7/31/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/11/2026
Exicure, Inc. stock logo
XCUR
Exicure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
5/28/2026
Exicure, Inc. stock logo
XCUR
Exicure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$290K27.80N/AN/A$1.52 per share0.42
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$10K863.29N/AN/A$2.04 per share0.64
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$3.33M0.64N/AN/A($7.68) per share-0.05
Exicure, Inc. stock logo
XCUR
Exicure
$500K15.07N/AN/A$0.62 per share1.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$12.60M-$1.08N/AN/AN/A-4,405.59%-47.60%-40.97%11/11/2026 (Estimated)
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$5.99M-$2.07N/AN/AN/AN/A-86.52%-81.96%11/6/2026 (Estimated)
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$34.35M-$5.19N/AN/AN/A-665.19%N/A-124.15%N/A
Exicure, Inc. stock logo
XCUR
Exicure
-$4.95M-$1.32N/AN/AN/AN/A-237.91%-61.98%N/A

Latest CLSD, APRE, CELZ, and XCUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Exicure, Inc. stock logo
XCUR
Exicure
-$18.60-$0.18+$18.42-$0.18$1.64 millionN/A
8/12/2026Q2 2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.1775-$0.07+$0.1075-$0.07$0.25 millionN/A
8/7/2026Q2 2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$0.39-$0.41-$0.02-$0.41N/AN/A
5/29/2026Q1 2026
Exicure, Inc. stock logo
XCUR
Exicure
-$18.60-$0.29+$18.31-$0.29$1.64 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
N/AN/AN/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/AN/AN/AN/AN/A
Exicure, Inc. stock logo
XCUR
Exicure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
13.56
13.56
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
N/A
12.90
12.90
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/A
3.87
3.87
Exicure, Inc. stock logo
XCUR
Exicure
N/A
0.56
0.56

Institutional Ownership

CompanyInstitutional Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
1.42%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
18.75%
Exicure, Inc. stock logo
XCUR
Exicure
42.82%

Insider Ownership

CompanyInsider Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
10.49%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
1.00%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
6.70%
Exicure, Inc. stock logo
XCUR
Exicure
52.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
712.59 million11.27 millionNo Data
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
56.59 million6.53 millionNot Optionable
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
305.23 million4.89 millionOptionable
Exicure, Inc. stock logo
XCUR
Exicure
506.55 million3.09 millionNot Optionable

Recent News About These Companies

Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics
August 3, 2026  |  quiverquant.comQ
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
August 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337599/33289/en/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance.html
Exicure Inc (NASDAQ: XCUR) - Share Price and Research
July 15, 2026  |  intelligentinvestor.com.auI
Exicure Reaches Preliminary Settlement in Derivative Lawsuits
July 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XCUR/pressreleases/1140488/exicure-reaches-preliminary-settlement-in-derivative-lawsuits/
Exicure Announces Board and Committee Changes
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319699/33289/en/exicure-announces-board-and-committee-changes.html
Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
June 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68739298-exicure-inc-exicure-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-requirement-399.htm
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
June 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/exicure-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-requirement-1036240531
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
June 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/10/3310084/33289/en/exicure-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-requirement.html
Exicure Regains Nasdaq Compliance After Late Quarterly Filing
June 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/exicure-regains-nasdaq-compliance-after-late-quarterly-filing?utm_source=marketbeat.com&utm_medium=referral
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304694/33289/en/exicure-announces-receipt-of-nasdaq-delinquency-notice-and-filing-of-form-10-q.html
Exicure delays quarterly filing, trims quarterly loss
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/exicure-delays-quarterly-filing-trims-quarterly-loss?utm_source=marketbeat.com&utm_medium=referral
Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies
April 22, 2026  |  quiverquant.comQ
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3279497/33289/en/exicure-announces-co-development-agreement-with-adbiotech-for-burixafor-gpc-100.html
Exicure Inc.
April 13, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/xcur/company-people
Exicure Strengthens Leadership With New COO and Director
April 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/exicure-strengthens-leadership-with-new-coo-and-director?utm_source=marketbeat.com&utm_medium=referral
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
April 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/02/3267814/33289/en/summary-notice-of-pendency-and-proposed-settlement-of-stockholder-derivative-actions.html
Exicure, Inc. Reports 2025 Financial Results and Announces Need for Additional Financing
March 25, 2026  |  quiverquant.comQ
Exicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional Financing
March 25, 2026  |  quiverquant.comQ
Exicure, Inc. Reports Full Year 2025 Financial Results
March 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/25/3262597/33289/en/exicure-inc-reports-full-year-2025-financial-results.html
Exicure, Inc. Reports Full Year 2025 Financial Results
March 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/25/3262598/33289/en/exicure-inc-reports-full-year-2025-financial-results.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$0.64 +0.00 (+0.03%)
As of 08/21/2026 03:59 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Creative Medical Technology stock logo

Creative Medical Technology NASDAQ:CELZ

$1.31 +0.03 (+2.34%)
As of 08/21/2026 04:00 PM Eastern

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Clearside Biomedical stock logo

Clearside Biomedical NASDAQ:CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Exicure stock logo

Exicure NASDAQ:XCUR

$1.15 -0.15 (-11.54%)
As of 08/21/2026 04:00 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas